This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters To the Editor

Combination Therapy: Is Clinical Practice Leading the Way?

Ron Welch, MScPharm; and Mark Snaterse, BScPharm

Published: January 15, 2003

Article Abstract

Letter to the Editor

Sir: In "Antipsychotic Polypharmacy: Squandering Precious Resources?" Dr. Stahl’s primary recommendation that we should give adequate and extended trials of atypical antipsychotics as alternatives to combination therapy is good advice and no doubt largely accepted in clinical practice. However, the recommendation to try some agents at higher doses, particularly olanzapine and quetiapine, suffers the same difficulties the author noted for combination therapy. Namely, this option is not supported by good controlled data, atypicality may be compromised, and the cost increases dramatically.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 64

Quick Links: Psychopharmacology

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...